Holen Sie sich die Stockscreener-App
10.58
0.99%
0.1011
Schlusskurs vom Vortag:
$10.48
Offen:
$10.55
24-Stunden-Volumen:
444.45K
Relative Volume:
0.24
Marktkapitalisierung:
$1.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-22.51
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
+1.28%
1M Leistung:
-7.00%
6M Leistung:
-40.77%
1J Leistung:
-26.76%
1-Tages-Spanne:
$10.23
$10.79
1-Wochen-Bereich:
$10.01
$10.88
52-Wochen-Spanne:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
10.58 | 1.04B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.94 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.80 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.57 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.49 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Responsive Playbooks and the SPRY Inflection - Stock Traders Daily
Update Recap: Will ARS Pharmaceuticals Inc stock recover after earningsJuly 2025 Snapshot & Capital Efficient Trade Techniques - baoquankhu1.vn
Pullback Watch: Will ARS Pharmaceuticals Inc stock recover after earnings2025 Top Gainers & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
ARS Pharmaceuticals Reports Q3 2025 Financial Results - MSN
Valuation Update: Is ARS Pharmaceuticals Inc a top pick in the sectorInsider Selling & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Rallies: Can ARS Pharmaceuticals Inc generate free cash flowJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Pullback Watch: Is ARS Pharmaceuticals Inc attractive at current valuationJuly 2025 Action & Weekly Consistent Profit Watchlists - baoquankhu1.vn
What are ARS Pharmaceuticals Inc.’s earnings expectationsTrade Exit Report & Reliable Breakout Forecasts - mfd.ru
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free ... - nrtoday.com
California K-12 schools get free needle-free epinephrine nasal spray - Stock Titan
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray - simplywall.st
Understanding the Setup: (SPRY) and Scalable Risk - Stock Traders Daily
Is ARS Pharmaceuticals Inc a top pick in the sector2025 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Sell Signal: Is ARS Pharmaceuticals Inc stock a falling knife or bargain buy2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Targets Report: What analysts say about ARS Pharmaceuticals Inc stock2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 12.3%Should You Sell? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump - Yahoo Finance
There's No Escaping ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) Muted Revenues Despite A 25% Share Price Rise - 富途牛牛
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - simplywall.st
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Finviz
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Sahm
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpShould You Buy? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Approval Expands Neffy Allergy Market Reach - Sahm
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
What drives ARS Pharmaceuticals Inc stock priceVolatility Index Analysis & Access High Yield Alerts - earlytimes.in
ARS Pharmaceuticals, Inc.Common Stock (NQ: SPRY - FinancialContent
ARS Pharmaceuticals, Inc. (SPRY): Investor Outlook Reveals a Compelling 162% Upside Potential - DirectorsTalk Interviews
ARS Pharma’s neffy nasal spray approved in China... - The Pharma Letter
The Technical Signals Behind (SPRY) That Institutions Follow - Stock Traders Daily
ARS Pharmaceuticals Stock Pre-Market (+4.4%) : 'neffy' Nasal Spray Approved in China - Trefis
Is ARS Pharmaceuticals a buy? - Cantech Letter
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - simplywall.st
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg - Yahoo Finance
China approves first community use epinephrine nasal spray for allergies By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 3.4%Time to Buy? - MarketBeat
ARS Pharma Receives Approval For Neffy In China, Expanding Global Reach - Nasdaq
ARS Pharmaceuticals Wins China Approval for First Community-Use Epinephrine for Allergic Reactions - MarketScreener
China approves first community use epinephrine nasal spray for allergies - Investing.com
ARS Pharmaceuticals' neffy Approved as First Epinephrine Nasal Spray for Out-of-Hospital Use in China - Quiver Quantitative
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - The Manila Times
neffy® (epinephrine nasal spray) Approved in China as the - GlobeNewswire
ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Trading Systems Reacting to (SPRY) Volatility - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Potential 152% Upside Captivates Investors - DirectorsTalk Interviews
With ARS Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
Is ARS Pharmaceuticals Inc. stock cheap at current valuationJuly 2025 Highlights & Reliable Volume Spike Alerts - Улправда
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 7.9% HigherWhat's Next? - MarketBeat
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.39%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):